Menlo Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Menlo Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,106	Closed	-$1.1M	–	32
2023 Q3	$1.1M	Hold	15,106	–	–	0.72%	25
2023 Q2	$1.26M	Buy	+15,106	New	+$1.26M	0.79%	28

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Menlo Advisors's XBI Position: Q4 2023 in Review

Menlo Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 15,106 shares — an estimated $1.1M sold.

Menlo Advisors first reported a position in XBI in Q2 2023 and held it in 2 quarters. The position peaked at $1.26M in Q2 2023. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Menlo Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Menlo Advisors sold 15,106 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $1.1M.
Menlo Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and held it in 2 quarters.
Menlo Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.26M in Q2 2023.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Menlo Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.